ALT5 Sigma Past Earnings Performance
Past criteria checks 0/6
ALT5 Sigma has been growing earnings at an average annual rate of 1.4%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 45.1% per year.
Key information
1.4%
Earnings growth rate
35.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -45.1% |
| Return on equity | -77.4% |
| Net Margin | -262.3% |
| Last Earnings Update | 28 Sep 2024 |
Recent past performance updates
Recent updates
Does ALT5 Sigma (NASDAQ:ALTS) Have A Healthy Balance Sheet?
Nov 15
JanOne Inc.'s (NASDAQ:JAN) Share Price Boosted 153% But Its Business Prospects Need A Lift Too
Mar 31JanOne Inc. (NASDAQ:JAN) Stock Catapults 75% Though Its Price And Business Still Lag The Industry
Feb 14Shareholders May Be A Bit More Conservative With JanOne Inc.'s (NASDAQ:JAN) CEO Compensation For Now
Oct 03JanOne to acquire Soin Therapeutics
Sep 16Does JanOne (NASDAQ:JAN) Have A Healthy Balance Sheet?
Aug 17Health Check: How Prudently Does JanOne (NASDAQ:JAN) Use Debt?
Mar 21Is JanOne (NASDAQ:JAN) Using Debt In A Risky Way?
Nov 19JanOne adds Nicholas Goeders to scientific advisory board
Jun 15JanOne advances toward initiation of mid-stage peripheral artery disease trial
Jun 08JanOne under pressure on pricing $6M stock offering
Jan 29Revenue & Expenses Breakdown
How ALT5 Sigma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 28 Sep 24 | 7 | -19 | 11 | 0 |
| 29 Jun 24 | 2 | -18 | 8 | 0 |
| 30 Mar 24 | 0 | -19 | 5 | 0 |
| 30 Dec 23 | 0 | -17 | 5 | 0 |
| 30 Sep 23 | 0 | 5 | 4 | 0 |
| 01 Jul 23 | 0 | 5 | 4 | 0 |
| 01 Apr 23 | 0 | 5 | 4 | 0 |
| 31 Dec 22 | 0 | 8 | 3 | 0 |
| 01 Oct 22 | 11 | 2 | 5 | 0 |
| 02 Jul 22 | 23 | 2 | 7 | 0 |
| 02 Apr 22 | 31 | -1 | 9 | 0 |
| 01 Jan 22 | 40 | -3 | 12 | 0 |
| 02 Oct 21 | 39 | -6 | 14 | 0 |
| 03 Jul 21 | 39 | -6 | 16 | 0 |
| 03 Apr 21 | 34 | -6 | 16 | 0 |
| 02 Jan 21 | 34 | -8 | 18 | 0 |
| 26 Sep 20 | 36 | -12 | 20 | 0 |
| 27 Jun 20 | 34 | -13 | 20 | 0 |
| 28 Mar 20 | 37 | -12 | 21 | 0 |
| 28 Dec 19 | 35 | -12 | 20 | 0 |
| 28 Sep 19 | 33 | -7 | 18 | 0 |
| 29 Jun 19 | 33 | -6 | 18 | 0 |
| 30 Mar 19 | 34 | -6 | 17 | 0 |
| 29 Dec 18 | 37 | -6 | 17 | 0 |
| 29 Sep 18 | 39 | -2 | 16 | 0 |
| 30 Jun 18 | 41 | 0 | 15 | 0 |
| 31 Mar 18 | 43 | 2 | 14 | 0 |
| 30 Dec 17 | 42 | 6 | 13 | 0 |
| 30 Sep 17 | -7 | 5 | 0 | 0 |
| 01 Jul 17 | 9 | 6 | 3 | 0 |
| 01 Apr 17 | 23 | 3 | 8 | 0 |
| 31 Dec 16 | 40 | 0 | 11 | 0 |
| 01 Oct 16 | 103 | -2 | 28 | 0 |
| 02 Jul 16 | 104 | -4 | 29 | 0 |
| 02 Apr 16 | 110 | -1 | 28 | 0 |
| 02 Jan 16 | 112 | -3 | 29 | 0 |
| 03 Oct 15 | 118 | -2 | 30 | 0 |
| 04 Jul 15 | 123 | -1 | 31 | 0 |
| 04 Apr 15 | 125 | -2 | 31 | 0 |
| 03 Jan 15 | 131 | 1 | 30 | 0 |
| 27 Sep 14 | 131 | 2 | 30 | 0 |
| 28 Jun 14 | 131 | 3 | 29 | 0 |
| 29 Mar 14 | 131 | 4 | 29 | 0 |
| 28 Dec 13 | 128 | 3 | 29 | 0 |
Quality Earnings: ALTS is currently unprofitable.
Growing Profit Margin: ALTS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALTS is unprofitable, but has reduced losses over the past 5 years at a rate of 1.4% per year.
Accelerating Growth: Unable to compare ALTS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALTS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: ALTS has a negative Return on Equity (-77.43%), as it is currently unprofitable.